A phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluation the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and older with a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation

This study evaluated the efficacy, pharmacodynamics (PD) and safe-ty of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.